Plain-English translation of NCT07484269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a registry study that follows patients with advanced prostate cancer who are receiving lutetium (177Lu) vipivotide tetraxetan, a targeted radiation treatment for this disease. The study collects real-world information from doctors and hospitals across multiple countries to understand how the medication is being used, what doses patients receive, and how well it works for different patients. Researchers will use artificial intelligence to help gather and analyze this data efficiently over a five-year period.
While this medication has been approved for advanced prostate cancer, doctors and researchers want to better understand how it performs in everyday clinical practice with diverse patient populations. This registry will provide insights into treatment patterns, patient outcomes, and real-world effectiveness that can help improve care for future patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not receive any new treatment — instead, your doctors would share your existing medical records and treatment information with the registry over a five-year follow-up period. This includes information about your cancer status, how you're tolerating the medication, your test results, and your clinical outcomes. You may be asked to complete surveys or allow researchers to access your hospital records, but there are no additional clinic visits or procedures required beyond your regular prostate cancer care.
AI-generated summary from trial data · Oct 31, 2026 · Not medical advice
Switzerland
Novartis Pharmaceuticals
Enrollment target
~753 participants
Started
September 2026
Primary completion
July 2031
Sex
Male only
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.